Volume 12, Issue 1, Pages 21-29 (January 2011) Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial Prof Jack Cuzick, PhD, Ivana Sestak, PhD, Prof Sarah E Pinder, MD, Prof Ian O Ellis, MD, Sharon Forsyth, BSc, Prof Nigel J Bundred, MD, Prof John F Forbes, MD, Hugh Bishop, MD, Prof Ian S Fentiman, MD, William D George, MD The Lancet Oncology Volume 12, Issue 1, Pages 21-29 (January 2011) DOI: 10.1016/S1470-2045(10)70266-7 Copyright © 2011 Elsevier Ltd Terms and Conditions
Figure 1 Trial profile T=tamoxifen. R=radiotherapy. CT=control group for tamoxifen. CR=control group for radiotherapy. The Lancet Oncology 2011 12, 21-29DOI: (10.1016/S1470-2045(10)70266-7) Copyright © 2011 Elsevier Ltd Terms and Conditions
Figure 2 Kaplan-Meier curve for cumulative incidence and annual hazard plot of all breast events in the tamoxifen comparison The Lancet Oncology 2011 12, 21-29DOI: (10.1016/S1470-2045(10)70266-7) Copyright © 2011 Elsevier Ltd Terms and Conditions
Figure 3 Forest plot for new breast events in the tamoxifen comparison stratified by whether or not patients received radiotherapy HR=hazard ratio. DCIS=ductal carcinoma in situ. The Lancet Oncology 2011 12, 21-29DOI: (10.1016/S1470-2045(10)70266-7) Copyright © 2011 Elsevier Ltd Terms and Conditions
Figure 4 Kaplan-Meier curve for cumulative incidence and annual hazard plot of all breast events in the radiotherapy comparison The Lancet Oncology 2011 12, 21-29DOI: (10.1016/S1470-2045(10)70266-7) Copyright © 2011 Elsevier Ltd Terms and Conditions
Figure 5 Forest plot for new breast events in the radiotherapy comparison stratified by whether or not patients received tamoxifen HR=hazard ratio. DCIS=ductal carcinoma in situ. The Lancet Oncology 2011 12, 21-29DOI: (10.1016/S1470-2045(10)70266-7) Copyright © 2011 Elsevier Ltd Terms and Conditions